Charles Schwab Investment Management Inc. Sells 140,813 Shares of Harvard Bioscience, Inc. $HBIO

Charles Schwab Investment Management Inc. reduced its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 58.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 98,883 shares of the medical instruments supplier’s stock after selling 140,813 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.22% of Harvard Bioscience worth $56,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Focus Partners Wealth purchased a new stake in Harvard Bioscience in the fourth quarter worth $28,000. Jane Street Group LLC increased its position in Harvard Bioscience by 55.5% in the fourth quarter. Jane Street Group LLC now owns 35,769 shares of the medical instruments supplier’s stock worth $75,000 after buying an additional 12,767 shares during the last quarter. Bank of America Corp DE boosted its position in Harvard Bioscience by 44.4% during the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after purchasing an additional 11,948 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Harvard Bioscience during the fourth quarter worth about $137,000. Finally, AMH Equity Ltd boosted its position in Harvard Bioscience by 35.5% during the first quarter. AMH Equity Ltd now owns 3,387,355 shares of the medical instruments supplier’s stock worth $1,917,000 after purchasing an additional 887,355 shares during the period. 80.87% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HBIO. Benchmark cut their target price on shares of Harvard Bioscience from $4.50 to $3.00 and set a “speculative buy” rating for the company in a research report on Tuesday, May 13th. Wall Street Zen lowered shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, August 30th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Harvard Bioscience has a consensus rating of “Moderate Buy” and an average target price of $3.00.

Harvard Bioscience Stock Performance

NASDAQ:HBIO opened at $0.47 on Friday. The firm has a market capitalization of $20.84 million, a price-to-earnings ratio of -0.36 and a beta of 1.54. Harvard Bioscience, Inc. has a 52-week low of $0.28 and a 52-week high of $3.04. The stock has a fifty day moving average of $0.48 and a 200 day moving average of $0.51.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.